close

Agreements

Date: 2018-09-14

Type of information: Services contract

Compound: Edit-R™ crRNA libraries

Company: Horizon Discovery (UK) AstraZeneca (UK)

Therapeutic area: Technology - Services

Type agreement: services contract

Action mechanism:

  • genome editing services. Horizon’s Edit-R CRISPR-Cas9 synthetic crRNA libraries for both knockout (loss-of-function) and activation (gain-of-function) enable whole genome analysis in an arrayed format, allowing researchers to carry out high-content, multiparametric analyses on a one-well-per-gene basis. The portfolio includes catalog libraries for popular human and mouse gene families, in addition to druggable gene targets and the whole human genome. Bespoke collections are also available to support researchers working with a specialized gene target list.

Disease:

Details:

  • • On September 14, 2018, Horizon Discovery Group, a global leader in gene editing and gene modulation technologies, announced AstraZeneca has adopted its Edit-R™ crRNA libraries as part of AstraZeneca’s drive to establish a functional genomics discovery platform. AstraZeneca also joins the Genomics Discovery Initiative (GDI), a collaborative functional genomics screening community facilitated by Horizon.
  • AstraZeneca has been evaluating Horizon’s Edit-R human whole genome crRNA library for gene knockout since late 2017, and will soon add the Company’s platform of arrayed synthetic crRNA libraries for CRISPR-mediated transcriptional activation (CRISPRa). The libraries offer a powerful tool for functional genomic screens in drug discovery, providing deeper insight into biological mechanisms for the purpose of understanding disease progression, host-pathogen relationships, drug interactions, and pathway analysis.
 

Financial terms:

Latest news:

Is general: Yes